Uncategorized
Allergan to acquire Oculeve in all-cash transaction
Allergan and Oculeve have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction, according to press release from Allergan. Under this agreement, Allergan will acquire Oculeve for an upfront payment of $125 million and commercialization milestone payments related to Oculeve’s OD-01, a noninvasive nasal neurostimulation device that increases tear production in patients with dry eye disease.